Advertisement
Thomas Parr, Ph.D., Chief Scientific Officer of Targanta Therapeuticscommented on the meeting: "We are very proud of the body of data beingpresented on behalf of Targanta at ICAAC this year-a true testament, webelieve, to the efforts and expertise of our scientists and collaborators. Wecontinue to be encouraged by the breadth of data supporting thedifferentiating characteristics of oritavancin and are pleased to be able topresent for the first time promising data on our pre-clinical osteomyelitisprogram."
Advertisement
Throughout the meeting, multiple posters will highlight the in vitroactivity of oritavancin, Targanta's investigational antibiotic for thetreatment of gram-positive infections, against a wide spectrum of antibioticsusceptible and resistant gram-positive bacteria. In addition, twopresentations at ICAAC will highlight Targanta's proprietary drug discoveryplatform, which utilizes bisphosphonate prodrugs of antibiotics to generatemolecules that deliver antibiotics directly to the bone.
The following abstracts have been accepted for poster or slidepresentation at ICAAC:
About Oritavancin
Oritavancin is a novel semi-synthetic lipoglycopeptide antibioticcandidate with potent bactericidal (killing) activity against a broad spectrumof gram-positive bacteria. The product candidate has been tested in over 1500patients and has completed two Phase 3 studies for the treatment ofcomplicated skin and skin structure infection (cSSSI) in which the primaryendpoints were met. Targanta believes oritavancin's properties may give itdistinct advantages over currently marketed therapies and expects to submit aNew Drug Application to the U.S. Food and Drug Administration in the firstquarter of 2008 seeking to commercialize oritavancin for the treatment ofcSSSI.
About Targanta Therapeutics
Targanta Therapeutics Corporation is a privately held biopharmaceuticalcompany focused on developing and commercializing innovative antibiotics totreat serious infections in the hospital and other institutional settings.The Company's pipeline includes oritavancin, a semi-synthetic lipoglycopeptideantibiotic, for which Targanta intends to seek U.S. regulatory approval inearly 2008, as well as a number of antibacterial agents in pre-clinicaldevelopment. The company has operations in Cambridge, MA, Indianapolis, IN,Montreal, Quebec, Canada and Toronto, Ontario, Canada. For furtherinformation about Targanta, visit the company's website at www.targanta.com.
Disclaimer
All forward-looking statements and other information included in thispress release are based on information available to Targanta as of the datehereof, and Targanta assumes no obligation to update any such forward-lookingstatements or information. Targanta's actual results could differ materiallyfrom those described in Targanta's forward-looking statements.Date Time Number Type Author Title Monday, 12:00- A-49 Poster Lehoux PK-PD of Oritavancin Sept. 17 1:00PM CDT (ORI) Against Streptococcus pneumoniae (SP) in a Murine-Pneumonia Infection Model A-50 Poster McKay In vitro Post Antibiotic Effect Studies of Oritavancin against
